-
EP3153178
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3153178
| EP3153178 - METHOD FOR TREATING CANCER PATIENTS USING FOLR1 TARGETED DRUG AND ANTIFOLATE, AND DRUG [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 03.04.2020 Database last updated on 29.07.2024 | |
| Former | Grant of patent is intended Status updated on 01.07.2019 | ||
| Former | Request for examination was made Status updated on 10.03.2017 | ||
| Former | The international publication has been made Status updated on 06.12.2016 | Most recent event Tooltip | 03.04.2020 | Application deemed to be withdrawn | published on 06.05.2020 [2020/19] | Applicant(s) | For all designated states Kyowa Kirin Co., Ltd. 1-9-2 Otemachi Chiyoda-ku Tokyo / JP | [2019/46] |
| Former [2017/15] | For all designated states Kyowa Hakko Kirin Co., Ltd. 1-6-1, Ohtemachi Chiyoda-ku Tokyo 100-8185 / JP | Inventor(s) | 01 /
ANDO Munetoshi c/o Head Office Kyowa Hakko Kirin Co. Ltd. 1-6-1 Ohtemachi Chiyoda-ku Tokyo 100-8185 / JP | 02 /
GOTO Keiko c/o Head Office Kyowa Hakko Kirin Co. Ltd. 1-6-1 Ohtemachi Chiyoda-ku Tokyo 100-8185 / JP | [2017/15] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [N/P] |
| Former [2017/15] | Tuxworth, Pamela M. J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | Application number, filing date | 15803346.4 | 05.06.2015 | [2017/15] | WO2015JP66328 | Priority number, date | US201462008726P | 06.06.2014 Original published format: US 201462008726 P | [2017/15] | Filing language | JA | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2015186823 | Date: | 10.12.2015 | Language: | JA | [2015/49] | Type: | A1 Application with search report | No.: | EP3153178 | Date: | 12.04.2017 | Language: | EN | [2017/15] | Search report(s) | International search report - published on: | JP | 10.12.2015 | (Supplementary) European search report - dispatched on: | EP | 21.11.2017 | Classification | IPC: | A61K45/00, A61K39/395, A61P35/00, A61K31/522, C07K16/28 | [2017/51] | CPC: |
A61K31/519 (EP,US);
C07K16/28 (US);
A61K31/522 (EP);
A61K39/395 (EP,US);
A61K39/3955 (US);
A61K45/00 (EP,US);
A61P35/00 (EP);
A61P43/00 (EP);
C07K2317/24 (US);
|
| Former IPC [2017/15] | A61K45/00, A61K31/519, A61K39/395, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/15] | Title | German: | VERFAHREN ZUR BEHANDLUNG VON KREBSPATIENTEN MITTELS FOLR1-GERICHTETEM WIRKSTOFF UND ANTIFOLAT SOWIE WIRKSTOFF | [2017/15] | English: | METHOD FOR TREATING CANCER PATIENTS USING FOLR1 TARGETED DRUG AND ANTIFOLATE, AND DRUG | [2017/15] | French: | PROCÉDÉ DE TRAITEMENT DE PATIENTS ATTEINTS DE CANCER AU MOYEN D'UN MÉDICAMENT CIBLÉ VERS FOLR1 ET D'ANTIFOLATE, ET MÉDICAMENT | [2017/15] | Entry into regional phase | 06.12.2016 | Translation filed | 06.12.2016 | National basic fee paid | 06.12.2016 | Search fee paid | 06.12.2016 | Designation fee(s) paid | 06.12.2016 | Examination fee paid | Examination procedure | 06.12.2016 | Examination requested [2017/15] | 06.12.2016 | Date on which the examining division has become responsible | 11.06.2018 | Amendment by applicant (claims and/or description) | 02.07.2019 | Communication of intention to grant the patent | 13.11.2019 | Application deemed to be withdrawn, date of legal effect [2020/19] | 20.12.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2020/19] | Fees paid | Renewal fee | 16.06.2017 | Renewal fee patent year 03 | 11.06.2018 | Renewal fee patent year 04 | 13.06.2019 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XY]WO2005080431 (MORPHOTEK INC [US], et al) [X] 1-4,7-10 * the whole document, in particular * * paragraph [0002] * * paragraph [0010] - paragraph [0019] * * paragraph [0111] - paragraph [0112] * * Examples * * paragraph [0131] - paragraph [0132] * * paragraph [0138] - paragraph [0141] * * Claims * [Y] 1-12; | [Y]WO2014036495 (IMMUNOGEN INC [US]) [Y] 1-12 * 'Summary of the Invention' * * paragraph 33 et seqq. * * paragraph [0041] * * paragraph [0053] * * paragraph [0066] - paragraph [0068] * * Examples * * Claims *; | [E]WO2016168440 (MORPHOTEK INC [US]) [E] 1-12 * the whole document, in particular * * 'Summary' * * paragraphs [0014] , [0 18] , [0 35] , [0 83] , [0 95] ** claims *; | [X] - JULIA D MALTZMAN ET AL, "Phase 2 double-blind, placebo-controlled study of three-weekly farletuzumab with a platinum containing doublet in subjects with previously untreated folate receptor alpha (FRA) expressing non-small-cell lung cancer (NSCLC).", 15TH WORLD CONFERENCE ON LUNG CANCER, (20131001), XP055283207 [X] 1-4,7-10 * the whole document * | [A] - MARIA INES NUNEZ ET AL, "High Expression of Folate Receptor Alpha in Lung Cancer Correlates with Adenocarcinoma Histology and Mutation", JOURNAL OF THORACIC ONCOLOGY, (20120413), vol. 7, no. 5, doi:10.1097/JTO.0b013e31824de09c, pages 833 - 840, XP055283276 [A] 1-12 * the whole document, in particular * * abstract * * Results * * Discussion * DOI: http://dx.doi.org/10.1097/JTO.0b013e31824de09c | International search | [XY] - THE JOURNAL OF NUCLEAR MEDICINE, (20060000), vol. 47, no. 12, pages 2057 - 2064, XP055363129 [X] 1-5, 7-11, 13-17 [Y] 4, 6, 10, 12, 16, 18 | [Y] - Expert Opinion on Drug Delivery, (20120000), vol. 9, no. 8, pages 901 - 908, XP 008184318 [Y] 4, 6, 10, 12, 16, 18 | [Y] - Cancer Chemother Pharmacol, (20120000), vol. 70, pages 113 - 120, XP035077240 [Y] 4, 6, 10, 12, 16, 18 DOI: http://dx.doi.org/10.1007/s00280-012-1890-2 |